Skip to main content
GRML
NASDAQ Life Sciences

Skaergaard's First S-K 1300 Report Lifts Indicated PdEq Ounces 31% for Greenland Mines

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.19
Mkt Cap
$28.574M
52W Low
$0.156
52W High
$1.38
52W Position info
22% above low
Off High info
86% below high
Rel. Volume info
7.6× avg
Market data snapshot near publication time

GRML sits 22% above its 52-week low of $0.156 on elevated volume (7.6× avg).

Summary

The first S-K 1300 technical report for Skaergaard reveals a 31% increase in Indicated PdEq ounces to 15 million and a 36% grade increase, enhancing the project's economic viability and regulatory standing.


Key Events · Product Development and Regulatory · GRML

  • 31% Increase in Indicated PdEq Ounces

    The 2026 Mineral Resource Estimate reports 15.00 Moz Indicated PdEq, up from 11.41 Moz in the 2022 estimate, with grade improving 36% to 3.04 g/t.

  • First S-K 1300 Compliant Report

    SLR Consulting completed the first S-K 1300 Technical Report Summary for Skaergaard, establishing a U.S. regulatory foundation and enabling advancement to an Initial Assessment.

  • Resource Upgrade Methodology

    The upgrade reflects updated metal prices (gold at $3,500/oz) and an improved block model that removes artificial dilution, resulting in a higher-grade, more economically robust resource.

  • Path to Initial Assessment

    The S-K 1300 conversion allows the company to proceed to an Initial Assessment, which will evaluate open-pit and underground mining scenarios, with 2026 field program data as key inputs.


Analysis · GRML · Life Sciences

The updated mineral resource estimate materially de-risks the Skaergaard project. A 31% jump in Indicated PdEq ounces to 15 million and a 36% grade increase to 3.04 g/t, driven by higher metal prices and a better geological model, significantly improves the project's economic potential. This S-K 1300 conversion provides a U.S. regulatory foundation, enabling the company to advance to an Initial Assessment. Against a backdrop of recent financial distress and a pending reverse stock split, this technical milestone strengthens the asset's value proposition and supports the company's strategic pivot toward critical minerals.

At the time of this filing, GRML was trading at $0.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $28.6M. The 52-week trading range was $0.16 to $1.38. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

GRML - Latest Insights

GRML
Jul 17, 2026, 11:12 AM EDT
Filing Type: 4
Importance Score:
8
GRML
Jul 17, 2026, 9:45 AM EDT
Source: PR Newswire
Importance Score:
8
GRML
Jul 15, 2026, 1:13 PM EDT
Source: FinanceWire
Importance Score:
7
GRML
Jun 23, 2026, 8:52 AM EDT
Filing Type: DEF 14A
Importance Score:
10
GRML
Jun 22, 2026, 6:39 PM EDT
Source: Reuters
Importance Score:
8